Sexual dysfunction, including loss of libido, anorgasmia, lack of vaginal lubrication, and erectile dysfunction, is one of the most commonly encountered adverse effects of treatment with fluoxetine and other SSRIs. While early clinical trials suggested a relatively low rate of sexual dysfunction, more recent studies in which the investigator actively inquires about sexual problems suggest that the incidence is >70%.  Symptoms of sexual dysfunction have been reported to persist after discontinuing SSRIs, although this is thought to be occasional.   
For most patients in whom a nonselective nonsteroidal antiinflammatory drug (NSAID) is chosen for short-term (no more than a month) or intermittent use, we prescribe naproxen, rather than other NSAIDs. Other nonselective NSAIDs (eg, ibuprofen) are reasonable alternatives, given the low baseline risk in such patients and lack of evidence regarding the cardiovascular risks of occasional low-dose use. Nonselective NSAIDs should be used at the lowest effective dose and for the shortest duration required in order to limit adverse events. We also prefer naproxen to other nonselective NSAIDs for patients who require long-term (over a month) use.